Skip to main content

Table 3 Follow-up period, number of events and incidence per 1000 person-years

From: Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study

Event Lispro(n = 1986) Aspart(n = 14,501) Glulisine(n = 1133)
Deaths 93 (234.4) 1192 (284.9) 33 (156.7)
Fatal CHD 29 (73.1) 352 (84.1) 13 (61.7)
Fatal CVD 34 (85.7) 424 (101.3) 14 (66.5)
CHD 196 (546.9) 1896 (489.9) 110 (571.9)
CVD 234 (668.4) 2312 (622.4) 132 (699.5)
Stroke 39 (99.7) 412 (100.1) 11 (52.6)
Heart failure 109 (289.0) 1177 (295.5) 46 (225.7)
Kidney failure 75 (193.8) 708 (173.4) 28 (135.8)
Hypoglycemia 15 (38.1) 234 (56.5) 12 (57.6)
Hyperglycemia 10 (25.3) 190 (45.8) 7 (33.4)
Maximum follow up time, years 6.3 6.4 6.1
Mean follow up time, years 2.0 2.9 1.9
Median follow up time, years 1.3 2.9 1.8
  1. Number of events (incidence per 1000 person-years). CHD coronary heart disease, CVD cardiovascular disease